ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · MYX.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 59.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Mayne Pharma Group Limited’s next earnings report is currently expected on Feb 24, 2027, with estimated earnings per share of -A$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mayne Pharma Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Feb 25, 2024 | -A$0.88-90.87% vs estimate | A$187.93M+16.72% vs estimate |
|---|
| Q4 2023 | Aug 30, 2023 | -A$2.01-251.75% vs estimate | A$82.40M-52.37% vs estimate |
|---|
| Q2 2023 | Feb 27, 2023 | -A$1.64-102.77% vs estimate | A$101.20M+26.98% vs estimate |
|---|
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
A$0.04-A$0.00 (-2.22%)
IDT Australia Limited’s quoted price sits in the lower half of its reported 52-week range, 29.03% below the high.
A$0.06+A$0.00 (+7.14%)
Little Green Pharma Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
